However, such investigation did not focus on the risk of sick leave for patients receiving the recombinant human thyroid stimulating hormone (rhTSH) therapy as a stimulation procedure to thyroid hormone withdrawal in the diagnostic follow-up of thyroid cancer patients. This evidence concerns the gene TG and thyroid gland carcinoma.